Insights On Drug Development

  1. ThioBridge™ Conjugates 4/14/2025

    Discover how Abzena’s ThioBridge™ technology is enabling the next generation of stable, scalable, and clinically advanced ADCs through site-specific conjugation.

  2. The Path To Regulatory Approval For AOCs 4/14/2025

    The development and manufacturability of antibody-oligonucleotide conjugates hinges on understanding and overcoming intricate chemistry and technical challenges.

  3. The Versatility Of ThioBridge™ Site-Specific Conjugation Technologies 4/14/2025

    Explore how advanced site-specific conjugation technologies are redefining the next generation of ADCs with enhanced stability, homogeneous DAR, and streamlined development.

  4. Optimizing DSP Development: Faster Timelines, Lower Costs, And High-Quality Processes 4/8/2025

    The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

  5. Optimize Your RNA-LNP Delivery With Ionizable Lipids 4/3/2025

    Ionizable lipids play a crucial role in optimizing LNP delivery. Discover how lipid nanoparticles revolutionize intracellular drug delivery to enhance RNA vaccines, cell therapies, protein replacement, and gene editing.

  6. Optimal Tech For Predicting Drug Responses At The Cellular Level 4/1/2025

    Explore how preserving spatial molecular information and leveraging AI-driven spatial-omics can transform treatment prediction, patient stratification, and personalized medicine.

  7. Unravelling Immunological Depths: Exploring Oxazolone-Induced Delayed-Type Hypersensitivity Model 3/28/2025

    Validating the oxazolone-induced DTH mouse model offers a critical platform for advancing the evaluation of therapeutic candidates for chronic inflammatory diseases, including atopic dermatitis.

  8. Enhancing mAb Processing With Protein A Membrane Chromatography For FIH Molecules 3/28/2025

    Our findings highlight this technology's potential in clinical development, providing greater flexibility, a smaller manufacturing footprint, and a more efficient purification process.

  9. Rapid And Simple Aggregate Removal Of mAbs Using Competitive Binding On CEX 3/28/2025

    To ensure the safety, efficacy, and stability of monoclonal antibody therapies, it is crucial to understand the factors driving aggregation and implement effective strategies to mitigate its impact.

  10. Therapeutic Effects Of An ALK5 Inhibitor In Preclinical Fibrosis Models 3/28/2025

    Our preclinical studies evaluating ALK5 inhibition in various mouse models of fibrosis have demonstrated differing degrees of therapeutic benefit, suggesting the potential for selective targeting.